Danaher’s (DHR) Market Perform Rating Reiterated at Raymond James

Raymond James reiterated their market perform rating on shares of Danaher (NYSE:DHR) in a report published on Monday morning, Marketbeat reports.

A number of other brokerages also recently issued reports on DHR. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a research report on Friday, December 13th. Stifel Nicolaus upped their price target on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. KeyCorp raised their price objective on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Scotiabank started coverage on Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target on the stock. Finally, Robert W. Baird decreased their price objective on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Seven analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Trading Down 1.4 %

NYSE DHR opened at $211.92 on Monday. Danaher has a one year low of $210.04 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The company has a market capitalization of $153.07 billion, a price-to-earnings ratio of 40.14, a price-to-earnings-growth ratio of 2.80 and a beta of 0.83. The company’s 50-day simple moving average is $234.50 and its two-hundred day simple moving average is $252.68.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the prior year, the business earned $2.09 earnings per share. Equities analysts forecast that Danaher will post 7.77 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were paid a dividend of $0.27 per share. The ex-dividend date was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.51%. Danaher’s payout ratio is 20.45%.

Insider Activity at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 10.90% of the company’s stock.

Hedge Funds Weigh In On Danaher

Several institutional investors and hedge funds have recently modified their holdings of DHR. Heck Capital Advisors LLC purchased a new stake in shares of Danaher in the fourth quarter valued at approximately $27,000. Decker Retirement Planning Inc. purchased a new stake in Danaher in the 4th quarter worth $31,000. Golden State Wealth Management LLC acquired a new position in Danaher during the fourth quarter worth $31,000. Strategic Financial Concepts LLC purchased a new position in Danaher during the fourth quarter valued at $31,000. Finally, Pineridge Advisors LLC grew its position in shares of Danaher by 63.3% in the fourth quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 57 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.